4/17
08:12 pm
lbrx
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]
Neutral
Report
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]
4/16
10:19 pm
lbrx
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham [Yahoo! Finance]
Medium
Report
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham [Yahoo! Finance]
4/10
09:00 am
lbrx
LB Pharmaceuticals (LBRX) is now covered by Craig Hallum. They set a "buy" rating and a $36.00 price target on the stock.
Medium
Report
LB Pharmaceuticals (LBRX) is now covered by Craig Hallum. They set a "buy" rating and a $36.00 price target on the stock.
4/9
04:16 pm
lbrx
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Medium
Report
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/9
04:05 pm
lbrx
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
Medium
Report
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
3/27
12:00 pm
lbrx
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
Medium
Report
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
3/27
09:53 am
lbrx
LB Pharmaceuticals (LBRX) had its price target raised by Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.
Medium
Report
LB Pharmaceuticals (LBRX) had its price target raised by Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.
3/26
04:39 pm
lbrx
LB Pharmaceuticals Inc GAAP EPS of -$0.45 [Seeking Alpha]
Medium
Report
LB Pharmaceuticals Inc GAAP EPS of -$0.45 [Seeking Alpha]
3/26
04:05 pm
lbrx
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Low
Report
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
3/25
08:00 am
lbrx
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
Medium
Report
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
3/9
08:25 am
lbrx
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors [Yahoo! Finance]
Medium
Report
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors [Yahoo! Finance]
3/9
08:00 am
lbrx
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
Medium
Report
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
3/4
04:31 pm
lbrx
LB Pharmaceuticals to Participate in Upcoming March Investor Events [Yahoo! Finance]
Medium
Report
LB Pharmaceuticals to Participate in Upcoming March Investor Events [Yahoo! Finance]
3/4
04:05 pm
lbrx
LB Pharmaceuticals to Participate in Upcoming March Investor Events
Medium
Report
LB Pharmaceuticals to Participate in Upcoming March Investor Events
2/10
04:41 pm
lbrx
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2/5
08:00 am
lbrx
LB Pharmaceuticals Announces $100.0 Million Private Placement
Medium
Report
LB Pharmaceuticals Announces $100.0 Million Private Placement
1/27
08:33 am
lbrx
LB Pharmaceuticals initiates Phase 2 trial of LB-102 [Yahoo! Finance]
Low
Report
LB Pharmaceuticals initiates Phase 2 trial of LB-102 [Yahoo! Finance]
1/26
08:00 am
lbrx
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
Medium
Report
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
1/21
08:00 am
lbrx
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
Low
Report
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel